Quote this publication Share Print

LUCENTIS

-
Opinions on drugs - Posted on Jan 24 2013

Reason for request

Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication in the treatment in adults of visual impairment due to macular oedema secondary to a branch retinal vein occlusion (BRVO) or a central retinal vein occlusion (CRVO).

-


Actual benefit

Important

The actual benefit of LUCENTIS 10 mg/ml injectable solution is substantial.


Improvement in actual benefit

IV (mineur)

LUCENTIS provides a minor improvement in actual benefit (IAB IV) compared with OZURDEX in the treatment of visual impairment due to a macular oedema secondary to retinal venous branch occlusion or a central retinal venous occlusion.


Contact Us

Évaluation des médicaments